Navigation Links
Trading in Regeneron Common Stock Halted
Date:6/17/2011

TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today.  The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is meeting today to discuss the company's Biologics License Application (BLA) for EYLEA™, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).  

Regeneron submitted a BLA for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the EYLEA BLA is August 20, 2011.

About EYLEAVascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

EYLEA (aflibercept ophthalmic solution), also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and highly potent blocker of these growth factors.  EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of the neovascular form of age-related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.  Bayer submitted an application for marketing authorization in Europe in wet AMD in June 2011.

Bayer HealthCare will market EYLEA™ outside the United States, where the companies will share equally the profits from any future sales of EYLEA.  Regeneron maintains exclusive rights to EYLEA in the United States.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shenzhen Wuzhou Changlian International Trading Co. Establishes Relationship with Hospital in Africa
2. Shenzhen Wuzhou Changlian International Trading Co. Announces Arrival of New Infrared Thermometer Series
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Internal Fixation Systems, Inc. Announces Form S-1 Declared Effective by SEC and Anticipated Quotation for Trading on OTCQB
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. Trading Halted Today in Optimer Pharmaceuticals Stock
7. Milestone Scientific Inc. Commences Trading on the OTC Pink
8. ERT to Change Trading Symbol to "ERT" Effective March 7, 2011 to Properly Align Business Brand
9. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
10. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
11. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... , May 25, 2016 ... & Expo earlier this month, the numbers and momentum ... continue to climb into the billions, more research and ... released 4th Edition State of Legal Marijuana Markets Report ... cannabis-focused data-analysis firm, much of the increase in sector ...
(Date:5/25/2016)... May 25, 2016 Inivata, ... precision of circulating tumour DNA (ctDNA) analysis to ... appointment of Professor Clive Morris as ... across the clinical development programme, scientific collaborations, and ... deliver significant improvements in clinical outcomes for patients. ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
(Date:5/26/2016)... New Hampshire (PRWEB) , ... May 26, 2016 , ... ... skin care products, has been honored with a 2016 When Work Works Award for ... prestigious award, part of the national When Work Works project administered by the Families ...
Breaking Medicine News(10 mins):